Medical devices firm EnteroMedics has published positive three-year data from its VBLOC DM2 study of vBloc neurometabolic therapy in obese patients with Type 2 diabetes, in the Journal of Diabetes and Obesity.
vBloc neurometabolic therapy is designed to employ vBloc system, a pacemaker-like device, to intermittently block the vagus nerves using high-frequency, low-energy electrical impulses.
Go deeper with GlobalData
The international, open-label, prospective, multi-centre DM2 study evaluated the safety and efficacy of vBloc therapy in 28 diabetic patients with obesity.
EnteroMedics president and chief executive officer Dan Gladney said: “We are encouraged by the strong three year results seen in the VBLOC DM2 study, as the data provides additional evidence of the benefit that vBloc therapy can offer to patients battling obesity and Type 2 diabetes.
“Obesity and Type 2 diabetes are two of the most serious societal health concerns throughout the world today, and innovative treatments like vBloc therapy have the potential to stem the tide against these dangerous and debilitating conditions.”
The study determined the average percentage excess weight loss (EWL), HbA1c (blood sugar), fasting plasma glucose (FPG, blood sugar) and blood pressure after activation of the device.
The data indicated no deaths, unanticipated adverse device effects, or life-threatening complications over the three year period.
The firm has secured the US Food and Drug Administration approval and CE mark for its vBloc system.
The vBloc therapy is approved for use in aiding weight loss in people aged 18 years and above, who are obese with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea.
